153 related articles for article (PubMed ID: 9807840)
1. Signal-transduction cascades as targets for therapeutic intervention by natural products.
Cardenas ME; Sanfridson A; Cutler NS; Heitman J
Trends Biotechnol; 1998 Oct; 16(10):427-33. PubMed ID: 9807840
[TBL] [Abstract][Full Text] [Related]
2. Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin.
Kumar R; Musiyenko A; Barik S
Mol Biochem Parasitol; 2005 May; 141(1):29-37. PubMed ID: 15811524
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
Cardenas ME; Cruz MC; Del Poeta M; Chung N; Perfect JR; Heitman J
Clin Microbiol Rev; 1999 Oct; 12(4):583-611. PubMed ID: 10515904
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression.
Kunz J; Hall MN
Trends Biochem Sci; 1993 Sep; 18(9):334-8. PubMed ID: 7694398
[TBL] [Abstract][Full Text] [Related]
5. Cellular signaling mechanisms for stimulation of growth hormone secretion and growth hormone primary transcripts by immunosuppressant agents, FK506 and cyclosporin A, in cultured rat pituitary cells.
Ohye H; Sato M; Murao K; Matsubara S; Tokuda M; Takahara J
Neuroimmunomodulation; 1998; 5(6):309-17. PubMed ID: 9762012
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Bierer BE
Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
[No Abstract] [Full Text] [Related]
7. Signaling cascades as drug targets in model and pathogenic fungi.
Bastidas RJ; Reedy JL; Morales-Johansson H; Heitman J; Cardenas ME
Curr Opin Investig Drugs; 2008 Aug; 9(8):856-64. PubMed ID: 18666033
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of action of cyclosporin A and FK506.
Ho S; Clipstone N; Timmermann L; Northrop J; Graef I; Fiorentino D; Nourse J; Crabtree GR
Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S40-5. PubMed ID: 8811062
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the glucocorticoid receptor subcellular localization by non steroidal compounds.
Prima V; Depoix C; Masselot B; Formstecher P; Lefebvre P
J Steroid Biochem Mol Biol; 2000; 72(1-2):1-12. PubMed ID: 10731632
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin.
Cardenas ME; Zhu D; Heitman J
Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):472-7. PubMed ID: 8591053
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways.
Cho CS; Elkahwaji J; Chang Z; Scheunemann TL; Manthei ER; Hamawy MM
Cell Signal; 2003 Jan; 15(1):85-93. PubMed ID: 12401523
[TBL] [Abstract][Full Text] [Related]
12. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells.
Le Bihan S; Marsaud V; Mercier-Bodard C; Baulieu EE; Mader S; White JH; Renoir JM
Mol Endocrinol; 1998 Jul; 12(7):986-1001. PubMed ID: 9658403
[TBL] [Abstract][Full Text] [Related]
13. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
Lawson B; Brewer JW; Hendershot LM
J Cell Physiol; 1998 Feb; 174(2):170-8. PubMed ID: 9428803
[TBL] [Abstract][Full Text] [Related]
14. FK506 binding proteins as targets in anticancer therapy.
Romano S; Di Pace A; Sorrentino A; Bisogni R; Sivero L; Romano MF
Anticancer Agents Med Chem; 2010 Nov; 10(9):651-6. PubMed ID: 21182472
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of new immunosuppressants.
Halloran PF
Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
[TBL] [Abstract][Full Text] [Related]
16. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.
Yorgin PD; Hartson SD; Fellah AM; Scroggins BT; Huang W; Katsanis E; Couchman JM; Matts RL; Whitesell L
J Immunol; 2000 Mar; 164(6):2915-23. PubMed ID: 10706677
[TBL] [Abstract][Full Text] [Related]
17. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs.
Blankenship JR; Steinbach WJ; Perfect JR; Heitman J
Curr Opin Investig Drugs; 2003 Feb; 4(2):192-9. PubMed ID: 12669381
[TBL] [Abstract][Full Text] [Related]
18. Geldanamycin, a heat shock protein 90-binding agent, disrupts Stat5 activation in IL-2-stimulated cells.
Xu W; Yu F; Yan M; Lu L; Zou W; Sun L; Zheng Z; Liu X
J Cell Physiol; 2004 Feb; 198(2):188-96. PubMed ID: 14603521
[TBL] [Abstract][Full Text] [Related]
19. The FK506-binding protein of the malaria parasite, Plasmodium falciparum, is a FK506-sensitive chaperone with FK506-independent calcineurin-inhibitory activity.
Kumar R; Adams B; Musiyenko A; Shulyayeva O; Barik S
Mol Biochem Parasitol; 2005 Jun; 141(2):163-73. PubMed ID: 15850699
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
